Heart failure & cardiomyopathies
Re-PERFUSE: Phase 1b Study of AZD3427, a Novel Relaxin Receptor Agonist, on Renal Perfusion in HF and Reduced Ejection Fraction (HFrEF) Patients
Study context
- Population
- Patients with heart failure (HF) and reduced ejection fraction (HFrEF) with reduced estimated glomerular filtration rate (eGFR) (EF ≤ 40% and eGFR of 30 to 90 mL/min/1.73 m², assessed by the CKD-EPI 2021)
- Planned comparison
- AZD3427 vs placebo on renal perfusion
- AZD3427n = 6
- Placebon = 6
Methodological detailsstudy design protocol (no results reported), positive control: intravenous dopamine
- Study design protocol (no results reported)
- Positive control: intravenous dopamine
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Re-PERFUSE: Phase 1b Study of AZD3427, a Novel Relaxin Receptor Agonist, on Renal Perfusion in HFrEF Patients. ESC Heart Fail. Published 4 September 2025. doi:10.
Summarised from the published abstract; every number is checked against it